



Attorney Docket No.: 126233.110

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :  
Joseph A. Bauer :  
Serial No. 10/761,870 : Group Art Unit: Not Yet Assigned  
Filed: January 21, 2004 : Examiner: Not Yet Assigned

For: COMPOSITION AND METHOD FOR AFFECTING  
METALLOCORRINOID UPTAKE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Mail Stop DD  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Copies are provided. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.


Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink, reading "Raymond A. Miller". The signature is written in a cursive, flowing style.

Raymond A. Miller  
Registration No. 42,891

Pepper Hamilton LLP  
One Mellon Bank Center  
50<sup>th</sup> Floor  
500 Grant Street  
Pittsburgh, PA 15219  
Telephone: (412) 454-5813  
Facsimile: (412) 281-0717  
Date: April 6, 2004



Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number	10/761,870		
				Filing Date	January 21, 2004		
				First Named Inventor	Bauer		
				Group Art Unit	Not yet assigned		
				Examiner Name	Not yet assigned		
Sheet	1	of 3			Attorney Docket Number	126233.110	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code (if known)				
	AA	5,936,082		Bauer	08-10-1999		
	AB	6,096,290		Collins et al.	02-06-2001		
	AC	6,183,723		Seetharam et al.	02-06-2001		
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number Kind Code (if known)				
	BA	EP 0220030	B1	Europe	10-10-1986		
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.					T
	CA	Amagaski, T., Green, R. & Jacobsen, D.W. Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells. Blood 76, 1380-1386. (1990).					
	CB	Bauer, J.A. Synthesis, characterization and nitric oxide release profile of nitrosylcobalamin: a potential chemotherapeutic agent. Anticancer Drugs 9, 239-244. (1998).					
	CC	Begley, J.A. & Hall, C.A. Measure of vitamin B12-binding proteins of plasma. I. Technigue. Blood 45, 281-286. (1975).					
	CD	Begley, J.A. & Hall, C.A. Masure of vitamin B12-binding proteins of plasma. II. Interpretation of patters in disease. Blood 45, 287-293. (1975).					
	CE	Blomquist, L., Flodh, H. & Ullberg, S. Uptake of labeled vitamin B 12 and 4-iodophenylalanine in some tumors of mice. Experientia 25, 294-296. (1969).					
	CF	Bose, S., Seetharam, S., Hammond, T.G. & Seetharam, B. Regulation of expression of transcobalamin II receptor in the rat. Biochem J 310, 923-929. (1995).					
	CG	Bose, S., Seetharam, S., & Seetharam, B. Membrane expression and interactions of human transcobalamin II receptor. J. Biol. Chem 270, 8152-8157. (1995).					
	CH	Bose, S., et al. In vitro and in vivo inactivation of transcobalamin II receptor by its antiserum. J. Biol. Chem 271, 4195-4200. (1996).					
	CI	Bose, S., Felix, J., Seetharam, S. & Seetharam, B. Dimerization of transcobalamin II receptor. Requirement of a structurally ordered lipid bilayer. J. Biol Chem 271, 11718-11725. (1996).					
	CJ	Bose, S. & Seetharam, B. Effect of disulfide bonds of transcobalamin II receptor on its activity and basolateral targeting in human intestinal epithelial Caco-2 cells. J Biol Chem 272, 20920-20928. (1997).					
	CK	Bose, S., Seetharam, S., Dahms, N.M. & Seetharam, B. Bipolar functional expression of transcobalamin II receptor in human intestinal epithelial Caco-2 cells. J. Biol Chem 272, 3538-3543. (1997).					
	CL	Bose, S. & Seetharam, B. Purification, membrane expression, and interactions of transcobalamin II receptor. Methods Enzymol 281, 281-289. (1997).					
	CM	Carmel, R. Extreme elevation of serum transcobalamin I in patients with metastatic cancer. N Engl J Med 292, 282-284. (1975).					
	CN	Chlichilia, K. et al. Caspace activation is required for nitric oxide-mediated, CD95 (APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 91, 4311-4320. (1998).					

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/761,870
				<b>Filing Date</b>	January 21, 2004
				<b>First Named Inventor</b>	Bauer
				<b>Group Art Unit</b>	Not yet assigned
				<b>Examiner Name</b>	Not yet assigned
<b>Sheet</b>	2	of 3	<b>Attorney Docket Number</b> 126233.110		
CO	Collins, D.A. et al. Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies. Mayo Clin Proc 75, 568-580. (2000).				
CP	Cooper, B.A., e.a. Selective uptake of specifically bound cobalt-58 vitamin B12 by human and mouse tumor cells. Nature 191, 393-395. (1961).				
CQ	Cooperman, J. e.a. Distribution of radioactive and nonradioactive vitamin B12 in the dog. Journal of Biological Chemistry 235, 191-194. (1960).				
CR	Cooperman, J. M. Distribution of radioactive and nonradioactive vitamin B12 in normal and malignant tissues of an infant with neuroblastoma. Cancer Res 21, 167-172. (1972).				
CS	DiGirolamo, P.M. & Huennekens, F.M. Transport of vitamin B12 into mouse leukemia cells. Arch Biochem Biophys 168, 386-393. (1975).				
CT	Flodh, H. & Ullberg, S. Accumulation of labeled vitamin B12 in some transplanted tumors. Int J Cancer 3, 694-699. (1968).				
CU	Gross, S.S. & Wolin, M.S. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 57, 737-769. (1995).				
CV	Huennekens, F.M., DiGirolamo, P.M., Fujii, K., Jacobsen, D.W. & Vitols, K.S. B12-dependent methionine synthetase as a potential target for cancer chemotherapy. Adv Enzyme Regul 14, 187-205. (1976).				
CW	Jensen, H.S., Gimseing, P., Pedersen, F. & Hippe, E. Transcobalamin II as an indicator of activity in metastatic renal adenocarcinoma. Cancer 52, 1700-1704. (1983).				
CX	Lindemans, J. et al. Uptake of transcobalamin II-bound cobalamin by HL-60 cells: effects of differentiation induction. Exp Cell Res 184, 449-460. (1989).				
CY	McLean, G.R. et al. Cobalamin analogues modulate the growth of leukemia cells in vitro. Cancer Res 57, 4015-4022. (1997).				
CZ	McLean, G.R., et al. Antibodies to transcobalamin II block in vitro proliferation of leukemic cells. Blood 89, 35-242. (1997).				
CAA	McLean, G.R., Williams, M.J., Woodhouse, C.S. & Ziltener, H.J. Transcobalamin II and in vitro proliferation of leukemic cells. Leuk Lymphoma 30, 101-109. (1998).				
CAB	Panthare, P.M. et al. Synthesis of cobalamin-biotin conjugates that vary in the position of cobalamin coupling. Evaluation of cobalamin derivative binding to transcobalamin II. Bioconjug Chem 7, 217-232. (1996).				
CAC	Quadros, E.V., Sai, P. & Rothenberg, S.P. Functional human transcobalamin II isoproteins are secreted by insect cells using the baculovirus expression system. Blood 81, 1239-1245. (1993).				
CAD	Quadros, E.V. & Jacobsen, D.W. The dynamics of cobalamin utilization in L-1210 mouse leukemia cells: a model of cellular cobalamin metabolism. Biochim Biophys Acta 1244, 395-403. (1995).				
CAE	Rabinowitz, R., Rachmilewitz, B., Rachmilewitz, M. & Schlesinger, M. Production of transcobalamin II by various murine and human cells in culture. Isr J Med Sci 18, 740-745. (1982).				
CAF	Rigby, C.A.B., M. Experimental Study of the relationship between vitamin B12 and two animal tumor systems. Brit. J. Cancer 17, 90-99. (1963).				
CAG	Ryel, E.M., Meyer, L.M. & Gams, R.A. Uptake and subcellular distribution of vitamin B12 in mouse L1210 leukemic lymphoblasts. Blood 44, 427-433. (1974).				
CAH	Seetharam, B., Bose, S. & Li, N. Cellular import of cobalamin (Vitamin B-12). J Nutr 129, 1761-1764. (1999).				
CAI	Seetharam, B. & Li, N. Transcobalamin II and its cell surface receptor. Vitam Horm 59, 337-366. (2000).				
CAJ	Shimizu, N., Hamazoe, R., Kanayama, H., Maeta, M. & Koga, S. Experimental study of antitumor effect of methyl-B12. Oncology 44, 169-173. (1987).				
CAK	Takahashi, K., Tavassoli, M. & Jacobsen, D.W. Receptor binding and internalization of immobilized transcobalamin II by mouse leukemia cells. Nature 288, 713-715. (1980).				
CAL	Tsao, C.S., Miyashita, K. & Young, M. Cytotoxic activity of cobalamin in cultured malignant and nonmalignant cells. Pathobiology 58, 292-296. (1990).				
CAM	Tsao, C.S. & Myashita, K. Influence of cobalamin on the survival of mice bearing ascites tumor. Pathobiology 61, 104-108. (1993).				
CAN	Waxman, S. & Gilbert, H.S. Characteristics of a novel serum vitamin-B12-binding protein associated with hepatocellular carcinoma. Br J Haematol 27, 229-239. (1974).				

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/761,870
				<b>Filing Date</b>	January 21, 2004
				<b>First Named Inventor</b>	Bauer
				<b>Group Art Unit</b>	Not yet assigned
				<b>Examiner Name</b>	Not yet assigned
<b>Sheet</b>	3	of 3	<b>Attorney Docket Number</b> 126233.110		
	CAO	Zittoun, J., Zittoun, R., Marquet, J. & Sultan, C. The three transcobalamin in myeloproliferative disorders and acute leukemia. Br J Haematol 31, 287-298. (1975).			
<b>Examiner Signature</b>				<b>Date Considered</b>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10**

**APPLICANT:** Bauer

**TITLE:** COMPOSITION AND METHOD FOR AFFECTING  
METALLOCORRINOID UPTAKE

**SERIAL NO.** 10/761,870

**ATTORNEY REF:** 126233.110

**DATE OF DEPOSIT:** April 6, 2004

I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT WITH COPIES OF REFERENCES CITED THEREIN IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed or printed name of person mailing paper or fee)

Documents Enclosed:

1. Information Disclosure Statement with cited references;
2. Certificate of Mailing;
3. Postcard